Investors can be forgiven in thinking that Boston Scientific's (NYSE: BSX ) on the right track. After all, this medical device stock has soared more than 58% year-to-date, rising as one of the top performers in the medical device industry in 2013. Yet underneath that rise in shares, Boston Scientific's hiding a struggling business and lagging sales.
Boston Scientific's interventional cardiology and cardiac rhythm management businesses -- its two top segments that make up more than 50% of total company revenue -- have slumped recently and saw sales decline in 2012. With pricing pressures ramping up and tough competition abounding, this company's struggling to turn its financials around. What does Boston Scientific need to do to look good as an investment again? Motley Fool contributor Dan Carroll tells you what Boston Scientific needs to focus on if this company wants to secure a bright future and reward shareholders with more of this year's stock gains.
Boston Scientific has performed well in the drug-eluting stent market, but no company's thriving in this industry like Abbott Labs. This company has changed forever, however, after losing its branded pharmaceutical business to a spinoff. If you're a current investor, or might be buying shares soon, make sure you truly understand the stock by reading The Motley Fool's brand new premium report on Abbott Labs. The report outlines all of the must-know opportunities and risks, along with a full year of analyst updates to keep you up to speed. Best of all, you can claim this report today by clicking here now.